Autologous bone marrow transplantation in T-cell malignancies: A case report involving in vitro treatment of marrow with a pan-T-cell monoclonal antibody

Herbert Kaizer, Ronald Levy, Charlotte Brovall, Curt I. Civin, Donald J. Fuller, Susan H. Hsu, Brigid G. Leventhal, Richard A. Miller, Eileen S. Milvenan, George W. Santos, Moody D. Wharam

Research output: Contribution to journalArticle

Abstract

The major obstacle to wider exploration of autologous bone mar-row transplantation in the lymphohematopoietic malignancies is the problem of subdetectable levels of tumor cells in the marrow of patients in complete remission. We report here a patient with a lymphoblastic lymphoma who exhibited a testicular and hematologic relapse. After reinduction therapy, marrow was collected from the patient, treated in vitro with a monoclonal anti T-cell anti-body (α-leu-1), and reinfused after supralethal doses of chemoradiotherapy. The patient exhibited prompt hematologic recovery and his post-transplant course has been benign over more than 20 months of follow-up. He has shown a persistent lymphocytosis of the bone marrow, but most of the marrow lymphocytes are morphologically mature and do not bear the surface antigens characteristic of his initial tumor. Measurements of immunologic function show persistently low levels of serum IgG, but recovery to normal levels of IgA and IgM. Lymphocyte proliferative responses to alloantigens and mitogens are normal. Moreover, the patient has not exhibited any tendency toward recur-rent infection. We conclude that treatment of bone marrow with a monoclonal antibody under conditions that lyse all tumor cells bearing the T-cell antigen, leu-1, is not associated with clinically significant inhibition of hematologic or immunologic recovery. Furthermore, the patient’s continued disease-free status suggests that the antibody treatment may have been effective in eliminating all clonogenic tumor from the remission marrow.

Original languageEnglish (US)
Pages (from-to)233-244
Number of pages12
JournalJournal of Biological Response Modifiers
Volume1
Issue number3
StatePublished - 1982

Fingerprint

Autologous Transplantation
Bone Marrow Transplantation
Bone Marrow
Monoclonal Antibodies
T-Lymphocytes
Neoplasms
Therapeutics
Lymphocytes
Mars
Lymphocytosis
Isoantigens
Viral Tumor Antigens
Chemoradiotherapy
Surface Antigens
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Mitogens
Immunoglobulin A
Immunoglobulin M
In Vitro Techniques
Immunoglobulin G

Keywords

  • Bone marrow transplantation
  • In vitro treatment
  • Lymphohematopoietic malignancies
  • T-cell antibody (α-leu-1)

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Pharmacology

Cite this

Autologous bone marrow transplantation in T-cell malignancies : A case report involving in vitro treatment of marrow with a pan-T-cell monoclonal antibody. / Kaizer, Herbert; Levy, Ronald; Brovall, Charlotte; Civin, Curt I.; Fuller, Donald J.; Hsu, Susan H.; Leventhal, Brigid G.; Miller, Richard A.; Milvenan, Eileen S.; Santos, George W.; Wharam, Moody D.

In: Journal of Biological Response Modifiers, Vol. 1, No. 3, 1982, p. 233-244.

Research output: Contribution to journalArticle

Kaizer, H, Levy, R, Brovall, C, Civin, CI, Fuller, DJ, Hsu, SH, Leventhal, BG, Miller, RA, Milvenan, ES, Santos, GW & Wharam, MD 1982, 'Autologous bone marrow transplantation in T-cell malignancies: A case report involving in vitro treatment of marrow with a pan-T-cell monoclonal antibody', Journal of Biological Response Modifiers, vol. 1, no. 3, pp. 233-244.
Kaizer, Herbert ; Levy, Ronald ; Brovall, Charlotte ; Civin, Curt I. ; Fuller, Donald J. ; Hsu, Susan H. ; Leventhal, Brigid G. ; Miller, Richard A. ; Milvenan, Eileen S. ; Santos, George W. ; Wharam, Moody D. / Autologous bone marrow transplantation in T-cell malignancies : A case report involving in vitro treatment of marrow with a pan-T-cell monoclonal antibody. In: Journal of Biological Response Modifiers. 1982 ; Vol. 1, No. 3. pp. 233-244.
@article{9fca9d82f0504babb357912e9fa607a0,
title = "Autologous bone marrow transplantation in T-cell malignancies: A case report involving in vitro treatment of marrow with a pan-T-cell monoclonal antibody",
abstract = "The major obstacle to wider exploration of autologous bone mar-row transplantation in the lymphohematopoietic malignancies is the problem of subdetectable levels of tumor cells in the marrow of patients in complete remission. We report here a patient with a lymphoblastic lymphoma who exhibited a testicular and hematologic relapse. After reinduction therapy, marrow was collected from the patient, treated in vitro with a monoclonal anti T-cell anti-body (α-leu-1), and reinfused after supralethal doses of chemoradiotherapy. The patient exhibited prompt hematologic recovery and his post-transplant course has been benign over more than 20 months of follow-up. He has shown a persistent lymphocytosis of the bone marrow, but most of the marrow lymphocytes are morphologically mature and do not bear the surface antigens characteristic of his initial tumor. Measurements of immunologic function show persistently low levels of serum IgG, but recovery to normal levels of IgA and IgM. Lymphocyte proliferative responses to alloantigens and mitogens are normal. Moreover, the patient has not exhibited any tendency toward recur-rent infection. We conclude that treatment of bone marrow with a monoclonal antibody under conditions that lyse all tumor cells bearing the T-cell antigen, leu-1, is not associated with clinically significant inhibition of hematologic or immunologic recovery. Furthermore, the patient’s continued disease-free status suggests that the antibody treatment may have been effective in eliminating all clonogenic tumor from the remission marrow.",
keywords = "Bone marrow transplantation, In vitro treatment, Lymphohematopoietic malignancies, T-cell antibody (α-leu-1)",
author = "Herbert Kaizer and Ronald Levy and Charlotte Brovall and Civin, {Curt I.} and Fuller, {Donald J.} and Hsu, {Susan H.} and Leventhal, {Brigid G.} and Miller, {Richard A.} and Milvenan, {Eileen S.} and Santos, {George W.} and Wharam, {Moody D.}",
year = "1982",
language = "English (US)",
volume = "1",
pages = "233--244",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Autologous bone marrow transplantation in T-cell malignancies

T2 - A case report involving in vitro treatment of marrow with a pan-T-cell monoclonal antibody

AU - Kaizer, Herbert

AU - Levy, Ronald

AU - Brovall, Charlotte

AU - Civin, Curt I.

AU - Fuller, Donald J.

AU - Hsu, Susan H.

AU - Leventhal, Brigid G.

AU - Miller, Richard A.

AU - Milvenan, Eileen S.

AU - Santos, George W.

AU - Wharam, Moody D.

PY - 1982

Y1 - 1982

N2 - The major obstacle to wider exploration of autologous bone mar-row transplantation in the lymphohematopoietic malignancies is the problem of subdetectable levels of tumor cells in the marrow of patients in complete remission. We report here a patient with a lymphoblastic lymphoma who exhibited a testicular and hematologic relapse. After reinduction therapy, marrow was collected from the patient, treated in vitro with a monoclonal anti T-cell anti-body (α-leu-1), and reinfused after supralethal doses of chemoradiotherapy. The patient exhibited prompt hematologic recovery and his post-transplant course has been benign over more than 20 months of follow-up. He has shown a persistent lymphocytosis of the bone marrow, but most of the marrow lymphocytes are morphologically mature and do not bear the surface antigens characteristic of his initial tumor. Measurements of immunologic function show persistently low levels of serum IgG, but recovery to normal levels of IgA and IgM. Lymphocyte proliferative responses to alloantigens and mitogens are normal. Moreover, the patient has not exhibited any tendency toward recur-rent infection. We conclude that treatment of bone marrow with a monoclonal antibody under conditions that lyse all tumor cells bearing the T-cell antigen, leu-1, is not associated with clinically significant inhibition of hematologic or immunologic recovery. Furthermore, the patient’s continued disease-free status suggests that the antibody treatment may have been effective in eliminating all clonogenic tumor from the remission marrow.

AB - The major obstacle to wider exploration of autologous bone mar-row transplantation in the lymphohematopoietic malignancies is the problem of subdetectable levels of tumor cells in the marrow of patients in complete remission. We report here a patient with a lymphoblastic lymphoma who exhibited a testicular and hematologic relapse. After reinduction therapy, marrow was collected from the patient, treated in vitro with a monoclonal anti T-cell anti-body (α-leu-1), and reinfused after supralethal doses of chemoradiotherapy. The patient exhibited prompt hematologic recovery and his post-transplant course has been benign over more than 20 months of follow-up. He has shown a persistent lymphocytosis of the bone marrow, but most of the marrow lymphocytes are morphologically mature and do not bear the surface antigens characteristic of his initial tumor. Measurements of immunologic function show persistently low levels of serum IgG, but recovery to normal levels of IgA and IgM. Lymphocyte proliferative responses to alloantigens and mitogens are normal. Moreover, the patient has not exhibited any tendency toward recur-rent infection. We conclude that treatment of bone marrow with a monoclonal antibody under conditions that lyse all tumor cells bearing the T-cell antigen, leu-1, is not associated with clinically significant inhibition of hematologic or immunologic recovery. Furthermore, the patient’s continued disease-free status suggests that the antibody treatment may have been effective in eliminating all clonogenic tumor from the remission marrow.

KW - Bone marrow transplantation

KW - In vitro treatment

KW - Lymphohematopoietic malignancies

KW - T-cell antibody (α-leu-1)

UR - http://www.scopus.com/inward/record.url?scp=0020309693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020309693&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0020309693

VL - 1

SP - 233

EP - 244

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 3

ER -